Panegra And Its Alternatives

Panegra

(Sildenafil citrate)

Composition:

Sildenafil citrate equivalent to

Sildenafil                              25mg

Panegra 50

Each tablet contains

Sildenafil citrate equivalent to

Sildenafil                              5omg

Panegra 100

Each tablet contains

Sildenafil citrate equivalent to

Sildenafil                              100mg

Description:

Panegra an oral therapy for erectile dysfunction, contains the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).sildenafil citrate is designated chemically as 1-[[3-(6,7- dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3-d]pyrimidine-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate and has a molecular weight of 666.7.

Indications

Panegra is indicated for the treatment of erectile dysfunction in men.

Contraindications:

Consistent with its known effect on thenitric oxide/cGMP path-way.  Panegra potentiates the hypotensive effect of nitrates, and its administration to patients who are using organic nitrates, either regularly and/or intermittently, in any form is therefore contraindicated.Panegra is also contraindicated in patients with a known hypersensitivity to any component of the tablet.

Pregnancy, Nursing Mothers and Pediatric use:

Panegra is not indicated for use in newborns, Children, or women.

Dosage:

For most patients, the recommended dose is 50mg taken, as needed, approximately 1 hour before sexual activity. However, Panegra may be taken anywhere from 4 hours to 0.5 hour before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100mg or decreased to 25mg. The maximum recommended dosing frequency is once per day.

Warnings:

There is a potential for cardiac risk of sexual activity In patients with preexisting cardiovascular diseases. Therefore treatments for erectile dysfunction, including Panegra; should  be generally used in men for whom sexual activity is in advisable because of their underlying cardiovascular status. Sildenafil citrate has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 8.4/5.5 mmHg). While this normally would expected to be of little consequence in most patients, prior to prescribing sildenafil citrate, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely    by such vasodilatory effects. Especially in combination with sexual activity. Similarly , Panegra should be prescribed with caution in the following group of patients since there is no controlled clinical trial data on the safety or efficacy of the drug in these patients.

11.     Patients who have suffered a myocardial infarction. Stroke, or  life-threatening arrhythmia within the last 6 months.

22.     Patients with resting hypotention (BP  < 90/50 ) or hypertension ( BP  > 170/110)

33.     Patients with cardiac failure or coronary artery disease causing unstable angina.

44.     Patients with retinitis pigmentosa ( a minority of these patients have genetic disorders of retinal phosphodiesterases).

Prolong erection greater than  4 hours and priapism ( painful erections greater than 6 hours in duration ) have been reported infrequently with sildenafil. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent lose of potency could result.